These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group. J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398 [Abstract] [Full Text] [Related]
3. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R. J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454 [Abstract] [Full Text] [Related]
5. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Jacobs E, Dalhoff A, Korfmann G. Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763 [Abstract] [Full Text] [Related]
13. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens]. Prado V, Giangrieco M, Durán C, Ojeda A, van Flaskamp R. Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240 [Abstract] [Full Text] [Related]
14. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Pfaller MA, Ehrhardt AF, Jones RN. Am J Med; 2001 Dec 17; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437 [Abstract] [Full Text] [Related]
15. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections. Appelbaum PC. Postgrad Med; 2000 Dec 17; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544 [Abstract] [Full Text] [Related]
16. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Jones RN, Fritsche TR, Sader HS, Stilwell MG. Diagn Microbiol Infect Dis; 2007 May 17; 58(1):9-17. PubMed ID: 17408903 [Abstract] [Full Text] [Related]
17. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Int J Antimicrob Agents; 2007 Jan 17; 29(1):56-61. PubMed ID: 17189096 [Abstract] [Full Text] [Related]
18. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey. Gonullu N, Catal F, Kucukbasmaci O, Ozdemir S, Torun MM, Berkiten R. Chemotherapy; 2009 Jan 17; 55(3):161-7. PubMed ID: 19390189 [Abstract] [Full Text] [Related]
19. Antimicrobial susceptibilities and distribution of resistance genes for beta-lactams and macrolides in Streptococcus pneumoniae isolated between 2002 and 2004 in Tokyo. Noguchi N, Tano J, Nasu Y, Koyama M, Narui K, Kamishima H, Saito T, Tsuyuki K, Sasatsu M. Int J Antimicrob Agents; 2007 Jan 17; 29(1):26-33. PubMed ID: 17189091 [Abstract] [Full Text] [Related]